Inventor
BROWN BOB DALE
US41 patents
⚠️ This page may combine multiple inventors who share the name “BROWN BOB DALE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
DICERNA PHARMACEUTICALS INC
30 patentsUS8349809B2Jan 8, 2013
Single stranded extended dicer substrate agents and methods for the specific inhibition of gene expression
DICERNA PHARMACEUTICALS INC162 citations99
US10144725B2Dec 4, 2018
Amine cationic lipids and uses thereof
DICERNA PHARMACEUTICALS INC21 citations94
US10870849B2Dec 22, 2020
Extended dicer substrate agents and methods for the specific inhibition of gene expression
DICERNA PHARMACEUTICALS INC7 citations84
US10837013B2Nov 17, 2020
Extended dicer substrate agents and methods for the specific inhibition of gene expression
DICERNA PHARMACEUTICALS INC5 citations84
US10131912B2Nov 20, 2018
Extended dicer substrate agents and methods for the specific inhibition of gene expression
DICERNA PHARMACEUTICALS INC15 citations84
US9549983B2Jan 24, 2017
Amine cationic lipids and uses thereof
DICERNA PHARMACEUTICALS INC4 citations80
US12077756B2Sep 3, 2024
Extended dicer substrate agents and methods for the specific inhibition of gene expression
DICERNA PHARMACEUTICALS INC1 citations73
US11634713B2Apr 25, 2023
Extended dicer substrate agents and methods for the specific inhibition of gene expression
DICERNA PHARMACEUTICALS INC1 citations73
US11597929B2Mar 7, 2023
Extended dicer substrate agents and methods for the specific inhibition of gene expression
DICERNA PHARMACEUTICALS INC1 citations73
US11414664B2Aug 16, 2022
Extended dicer substrate agents and methods for the specific inhibition of gene expression
DICERNA PHARMACEUTICALS INC1 citations73
US11408003B2Aug 9, 2022
Extended dicer substrate agents and methods for the specific inhibition of gene expression
DICERNA PHARMACEUTICALS INC1 citations73
US11359198B2Jun 14, 2022
Extended dicer substrate agents and methods for the specific inhibition of gene expression
DICERNA PHARMACEUTICALS INC2 citations73
US10137201B2Nov 27, 2018
Process for formulating an anionic agent
DICERNA PHARMACEUTICALS INC4 citations71
US9217146B2Dec 22, 2015
Phase changing formulations of nucleic acid payloads
DICERNA PHARMACEUTICALS INC4 citations69
US12435336B2Oct 7, 2025
Compositions and methods for inhibiting LPA expression
DICERNA PHARMACEUTICALS INC0 citations62
US12252691B2Mar 18, 2025
Compositions and methods for inhibiting LPA expression
DICERNA PHARMACEUTICALS INC0 citations62
US11912996B2Feb 27, 2024
Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
DICERNA PHARMACEUTICALS INC0 citations62
US11851658B2Dec 26, 2023
Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
DICERNA PHARMACEUTICALS INC0 citations62
US11459566B1Oct 4, 2022
Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
DICERNA PHARMACEUTICALS INC0 citations62
US11408002B1Aug 9, 2022
Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
DICERNA PHARMACEUTICALS INC0 citations62
US11312961B1Apr 26, 2022
Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
DICERNA PHARMACEUTICALS INC0 citations62
US11312960B1Apr 26, 2022
Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
DICERNA PHARMACEUTICALS INC0 citations62
US11059807B2Jul 13, 2021
Amine cationic lipids and uses thereof
DICERNA PHARMACEUTICALS INC0 citations62
US11351265B2Jun 7, 2022
Process for formulating an anionic agent
DICERNA PHARMACEUTICALS INC0 citations60
US9206420B2Dec 8, 2015
Methods and compositions for the specific inhibition of HIF-1α by double-stranded RNA
DICERNA PHARMACEUTICALS INC1 citations52
US12529053B2Jan 20, 2026
Double-stranded nucleic acid inhibitor molecules with shortened sense strands
DICERNA PHARMACEUTICALS INC0 citations50
US12234456B2Feb 25, 2025
Compositions and methods for modulating APOC3 expression
DICERNA PHARMACEUTICALS INC0 citations50
US12084662B2Sep 10, 2024
Compositions and methods for modulating PNPLA3 expression
DICERNA PHARMACEUTICALS INC0 citations50
US11873488B2Jan 16, 2024
Double-stranded nucleic acid inhibitor molecules modified with Tm-increasing nucleotides
DICERNA PHARMACEUTICALS INC0 citations50
US9790498B2Oct 17, 2017
Phase changing formulations of nucleic acid payloads
DICERNA PHARMACEUTICALS INC0 citations48
PROMEGA BIOSCIENCES INC
6 patentsUS6638529B2Oct 28, 2003
Amide-based cationic lipids
PROMEGA BIOSCIENCES INC45 citations95
US6339173B1Jan 15, 2002
Amide-based cationic lipids
PROMEGA BIOSCIENCES INC50 citations95
US6251939B1Jun 26, 2001
Carbamate-based cationic lipids
PROMEGA BIOSCIENCES INC66 citations95
US6034135AMar 7, 2000
Dimeric cationic lipids
PROMEGA BIOSCIENCES INC64 citations95
US6172049B1Jan 9, 2001
Phosphonic acid-based cationic lipids
PROMEGA BIOSCIENCES INC64 citations94
US6670393B2Dec 30, 2003
Carbamate-based cationic lipids
PROMEGA BIOSCIENCES INC19 citations92
GENTA INC
4 patentsUS6028188AFeb 22, 2000
Synthetic oligomers having chirally pure phosphonate internucleosidyl linkages mixed with non-phosphonate internucleosidyl linkages
GENTA INC251 citations95
US6020526AFeb 1, 2000
Amide-based cationic lipids
GENTA INC73 citations95
US5877220AMar 2, 1999
Amide-based oligomeric cationic lipids
GENTA INC71 citations95
US5958901ASep 28, 1999
Phosphonic acid-based cationic lipids
GENTA INC64 citations94